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Abstract
Background: Open esophagectomy (OE) is associated with significant morbidity and mortality. Minimally invasive
oesophagectomy (MIO) reduces complications in resectable esophageal cancer. The aim of this study is to explore
the superiority of MIO in reducing complications and in-hospital mortality than OE.
Methods: MEDLINE, Embase, Science Citation Index, Wanfang, and Wiley Online Library were thoroughly searched.
Odds ratio (OR)/weighted mean difference (WMD) with a 95% confidence interval (CI) was used to assess the
strength of association.
Results: Fifty-seven studies containing 15,790 cases of resectable esophageal cancer were included. MIO had less
intraoperative blood loss, short hospital stay, and high operative time (P < 0.05) than OE. MIO also had reduced
incidence of total complications; (OR = 0.700, 95% CI = 0.626 ~ 0.781, PV < 0.05), pulmonary complications (OR = 0.
527, 95% CI = 0431 ~ 0.645, PV < 0.05), cardiovascular complications (OR = 0.770, 95% CI = 0.681 ~ 0.872, PV < 0.05),
and surgical technology related (STR) complications (OR = 0.639, 95% CI = 0.522 ~ 0.781, PV < 0.05), as well as lower
in-hospital mortality (OR = 0.668, 95% CI = 0.539 ~ 0.827, PV < 0.05). However, the number of harvested lymph nodes,
intensive care unit (ICU) stay, gastrointestinal complications, anastomotic leak (AL), and recurrent laryngeal nerve
palsy (RLNP) had no significant difference.
Conclusions: MIO is superior to OE in terms of perioperative complications and in-hospital mortality.
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Background
A global incidence of esophageal cancer has increased
by 50% in the past two decades. Each year, around
482,300 people are diagnosed with esophageal cancer,
and 84.3% die of the disease worldwide [1, 2]. At
present, the primary method of treating patients with
esophageal cancer has been surgery. However, the
traditional open esophagectomy (OE) procedure has
high complication rates resulting in significant mor-
bidity and mortality [3, 4]. Various studies showed in-
hospital mortality between 1.2 and 8.8% [4–7], even
as high as 29% [8].
Minimally invasive oesophagectomy (MIO), which was
first described in the 1990s [9, 10], was attributed to be
superior in reducing postoperative outcomes, without
compromising oncological outcomes and avoiding thora-
cotomy and laparotomy. The basis of minimally invasive
techniques in esophageal surgery is to maintain the ther-
apy effectiveness and quality of traditional operations,
while reducing perioperative injury. Nevertheless, the
real benefits of minimally invasive approach for esopha-
gectomy are still controversial [11–13]. A number of
meta-analyses and even randomized controlled trials
demonstrated MIO to be superior in reducing risk of
postoperative outcomes, but their results are not very
consistent, especially on the issue of in-hospital mortal-
ity [14–30]. Furthermore, these studies ignored pre-
operative clinical data and other Chinese relevant
literatures. We, therefore, performed a meta-analysis
combining the relevant publications and comprehen-
sively assess the superiority of MIO.
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MEDLINE, Embase, Science Citation Index, Wanfang,
and Wiley Online Library were thoroughly searched with
terms “Minimally Invasive Esophagectomy” or “Open
Esophagectomy,” “Esophagectomy,””MIE,” “laparasc,”
“thoracosc,” “VATS,” “transhiatal” (date until May 2016).
Relevant literatures containing full text were back
tracked thoroughly, while abstracts and unpublished re-
ports were excluded.
Selections of studies
Inclusion criteria The inclusion criteria are as follows:
(1) randomized or non-randomized controlled studies
with parallel controls, (2) comparison on OE versus
MIO, (3) sufficient data of estimated odds ratios (ORs)/
weighted mean difference (WMD) and 95% confidence
intervals (CIs).
Exclusion criteria The exclusion criteria are as fol-
lows: (1) studies that were not compared or case re-
port, (2) incomplete literature, and (3) overlapped
studies.
Data extraction
Two investigators read all the included literatures care-
fully and extracted all the data, such as first author, pub-
lished year, numbers of case and controls, outcomes of
interest, etc. If two investigators have divergent ideas on
any data, the third investigator would be asked to check
and reach consensus on the data.
Outcomes of interest
(1)Definition of MIO was thoracoscopic/
laparotomy-assisted esophagectomy, hybrid
minimally invasive esophagectomy, total
thoracoscopic/hand-assisted thoracotomy,
hand-assisted laparotomy, or minilaparotomy/
laparoscopic esophagectomy.
(2) Preoperative clinical data included age, neoadjuvant
therapy, comorbidity, TNM staging, and gender.
(3) Postoperative data contained operative duration,
blood loss, intensive care unit (ICU) stay, hospital
stay, and harvested lymph nodes.
(4) The complications are as follows. (1) Mortality
included in-hospital mortality and 30-day mortality.
(2) Pulmonary complications included pneumonia,
respiratory failure, adult respiratory distress syn-
drome (ARDS), etc. (3) Cardiovascular complica-
tions included arrhythmia, heart failure, acute
myocardial infarction, deep vein thrombosis, pul-
monary embolism, etc. (4) Gastrointestinal compli-
cations included gastric tip necrosis, anastomotic
stricture, delayed gastric emptying, gastric volvulus,
etc. (5) Surgical technology related (STR) complica-
tions included splenic laceration, tracheal laceration,
pneumothorax, chylothorax, hemorrhage, etc.
Fig. 1 Study flow chart explaining the selection of 57 studies included in the meta-analysis
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Table 1 Characteristics of included studies in this meta-analysis
Study Year Country Cases Gender (M) Age, years NT NOS Hybrid Preoperative comorbidity (MIO/OE) TNM stage (MIO/OE)
(MIO/OE) (MIO/OE) (MIO/OE) (MIO/OE) Cardiovascular Pulmonary Diabetes 0 + I + II III + IV
Nguyen 2000 USA 18/36 7/29 64 ± 12/67 ± 8 9/9 6 MIE NR NR NR NR NR
Osugi 2003 Japan 77/72 64/57 63.7 ± 9 · 6/64 · ±9 · 3 NR 7 TA NR NR NR NR NR
Kunisaki 2004 Japan 15/30 12/21 62.3 ± 8.1/63 ± 6 NR 6 MIE NR NR NR NR NR
Bernabe 2004 USA 17/14 16/11 63.9 ± 13.5/64.1 ± 10.7 NR 6 TA NR NR NR NR NR
Van den Broek 2004 Netherlands 25/20 19/14 63 ± 8/64 ± 8 17/4 7 TA NR NR NR 8/10 17/10
Braghetto 2006 Chile 47/119 NR NR 0/0 8 MIE NR NR NR 41/80 6/39
Bresadola 2006 Italy 14/14 8/13 61.9 ± 7.7/59.3 ± 10.9 NR 6 MIE NR NR NR 11/6 3/8
Shiraishi 2006 Japan 116/37 94/31 61.5 ± 8.1/66.5 ± 9.3 26/10 7 Hybrid NR NR NR NR NR
Smithers 2007 Australia 332/114 267/104 64 (27–85)/62.5 (29–81) 136/29 8 Hybrid 76/22 NR 27/4 192/36 118/75
Benzoni 2007 Italy 9/13 6/11 63.6 ± 2.6/60.2 ± 2.4 6/6 8 TA NR 2/4 NR 9/7 0/6
Fabian 2008 USA 22/43 16/31 63 (46–86)/61 (35–82) 9/16 7 MIE NR NR NR 14/25 7/19
Parameswaran 2009 UK 50/30 45/21 67 (47–81)/68 (47–81) 32/12 8 MIE NR NR NR 27/17 23/13
Saha 2009 UK 16/28 13/24 65 (50–80)/64 (35–78) NR 8 MIE NR NR NR NR NR
Zingg 2009 Australia 56/98 45/71 66.3 ± 1.3/67.8 ± 1.1 40/48 8 MIE 4/7 13/35 6/12 35/47 21/42
Pham 2010 USA 44/46 41/33 63 ± 8.6/61 ± 10.7 29/23 6 MIE NR NR NR 20/20 20/19
Perry 2010 USA 21/21 18/17 69 ± 8/61 ± 9 NR 7 MIE NR NR NR NR NR
Hamouda 2010 UK 51/24 44/23 62/60 44/20 7 MIE NR NR NR NR NR
Safranek 2010 UK 75/46 53/38 60 (44–77)/64(41–74) 71/34 7 Hybrid NR NR NR 31/29 44/17
Schoppmann 2010 Australia 31/31 25/21 61.5 (36–75)/58.6 (34–77) 15/7 8 MIE 6/8 10/8 1/1 18/19 13/12
Schröder 2010 Germany 238/181 198/151 61.1 (60–62)/57.8 (56–59) 144/66 6 TA NR NR NR NR NR
Mehran 2011 USA 44/44 43/40 61.0 (42–79)/62.5 (38–83) 31/30 7 MIE NR NR NR 23/21 16/20
Berger 2011 USA 65/53 51/38 61 (41–78)/62 (40–86) 28/43 6 MIE NR NR NR 52/41 13/12
Lee 2011 Japan 74/64 73/61 59.7 ± 10.3/56.6 ± 11.6 47/52 8 Hybrid NR NR NR 54/49 20/15
Nafteux 2011 Belgium 65/101 52/81 63 (41–82)/64 (29–82) NR 8 MIE 11/24 6/13 6/12 NR NR
Yamasaki 2011 Japan 109/107 87/95 64.6 ± 8.5/64.7 ± 8.0 85/68 8 TA 20/20 11/13 10/6 NR NR
Biere 2012 Netherlands 59/56 43/46 62 (34–75)/62 (42–75) 59/56 8 MIE NR NR NR 31/26 15/19
Maas 2012 Netherlands 50/50 41/33 62.5 (57–69)/65 (57–69) 23/13 8 MIE NR NR NR 19/19 31/31
Briez 2012 France 140/140 110/117 NR 67/69 8 TA NR NR NR 92/89 48/51
Kinjo 2012 Japan 106/79 87/70 62.7 ± 7.4/63.3 ± 8.6 54/11 7 MIE NR NR NR 65/45 41/34
Mamidanna 2012 UK 1155/6347 892/4870 NR NR 7 MIE 400/2234 141/782 90/598 NR NR
Sihag 2012 USA 38/76 29/61 61.4 ± 8.1/63.3 ± 9.3 25/46 7 MIE 6/16 8/13 NR 29/53 9/23













Table 1 Characteristics of included studies in this meta-analysis (Continued)
Tsujimoto 2012 Japan 22/27 21/21 70 ± 5.4/67 ± 10.1 8/16 6 TA NR NR NR 12/14 10/13
Javidfar 2012 USA 92/165 71/122 65 (56–74)/68 (60–74) 51/96 7 MIE 9/23 9/23 22/35 65/96 27/69
Bailey 2013 UK 39/31 32/27 65 (37–78)/62 (38–78) 33/31 7 TA NR NR NR NR NR
Ichikawa 2013 Japan 152/163 129/145 63.8 ± 8.5/64.6 ± 8.6 54/64 8 TA 23/35 21/24 26/37 101/81 51/79
Kitagawa 2013 Japan 45/47 35/40 63 (47–77)/64 (39–83) 8/11 7 MIE NR NR 8/8 NR NR
Noble 2013 UK 53/53 43/45 66 (45–85)/64 (36–81) 13/11 8 MIE NR NR NR NR NR
Parameswaran 2013 UK 67/19 47/15 64 (45–84)/64 (51–77) 50/17 7 Hybrid NR NR NR 43/8 23/11
Takeno 2013 Japan 91/166 77/147 63.7/64.2 NR 8 TA NR NR NR NR NR
Kubo 2014 Japan 135/74 111/60 64.1 ± 8.2/62.2 ± 7.2 22/4 7 Hybrid 12/3 9/7 NR 112/41 23/33
Schneider 2014 UK 19/61 46/15 62.3 (35–74)/66.7 (45–79) 7/45 6 MIE NR NR NR 16/36 2/24
Daiko 2015 Japan 31/33 28/28 66 (49–78)/65 (49–76) NR 7 MIE NR NR NR 23/32 8/1
Kauppi 2015 Finland 74/79 59/68 66 (51–85)/63 (39–82) 61/62 8 MIE 14/17 12/14 17/13 28/25 46/54
Law 1997 China 18/63 13/55 66 (43–80)/63 (36–84) NR 7 MIE NR NR NR 5/15 13/45
Chen 2010 China 67/38 45/25 61 ± 7/66 ± 6 NR 7 MIE 15/4 10/3 9/2 42/15 25/23
Gao 2011 China 96/78 89/70 58.5 ± 7.3/59.1 ± 6.4 NR 6 MIE NR NR NR 54/40 42/38
Shen 2012 China 76/71 52/50 60.9 ± 9/62.6 ± 8.7 NR 6 MIE NR NR NR 41/44 35/27
Liu 2012 China 98/105 67/71 62.3 ± 10.1/65.8 ± 7.6 NR 6 MIE 13/18 40/37 6/8 51/43 47/62
Mao 2012 China 34/38 28/26 62/60 NR 6 TA NR NR NR 27/21 7/17
Wang 2012 China 260/322 194/232 61.6 ± 8.761.2 ± 8.8 37/44 6 MIE NR NR NR 201/234 59/88
MU 2014 China 176/142 116/106 60 (55–66)/59 (54–62) NR 6 MIE NR NR NR 120/109 56/33
Meng 2014 China 94/89 65/63 59.7 ± 9.3/61.1 ± 6.7 NR 7 MIE 11/14 27/31 12/10 56/50 38/39
Zhang 2014 China 60/61 48/47 62.4 ± 8/61.8 ± 8.4 NR 6 MIE NR NR NR 41/42 19/19
Chen 2015 China 59/59 42/40 57 (41–72)/56 (48–71) NR 7 MIE 4/2 1/0 2/3 56/55 3/4
Yang 2015 China 62/62 45/45 62 ± 9/62 ± 8 NR 7 MIE NR NR NR 44/43 18/19
Li 2015 China 89/318 66/227 73 (70–83)/73 (70–85) NR 7 MIE NR NR NR 64/188 25/126
NT neoadjuvant therapy, NOS Newcastle-Ottawa quality assessment scale, MIO minimally invasive oesophagectomy, including MIE,TA, and hybrid MIE, OE open esophagectomy, MIE total minimally invasive esophagec-













Table 2 Outcomes of complication in included studies
Study Total Pulmonary Circulatory system Digestive system AL RLNP STR Mortality
MIO/OE MIO/OE MIO/OE MIO/OE MIO/OE MIO/OE MIO/OE MIO/OE MIO/OE
Nguyen NR 2/6 1/1 1/2 3/4 0/4 0/1 0/1
Osugi 25/27 12/14 3/2 NR 2/1 11/9 4/4 NR
Kunisaki NR 0/1 NR NR 2/1 3/3 NR NR
Bernabe NR NR NR 7/8 NR NR NR NR
Van den Broek 14/18 2/2 NR 3/5 2/3 2/3 2/4 NR
Braghetto 18/72 7/22 0/3 4/6 3/17 0/2 1/0 3/13
Bresadola NR 1/2 1/0 NR 1/2 3/1 NR NR
Shiraishi NR 25/12 13/9 NR 12/9 42/10 NR 6/5
Smithers 207/76 106/44 60/24 83/9 17/11 8/0 25/14 7/3
Benzoni NR 0/2 NR 0/1 1/1 1/1 NR 0/1
Fabian 15/31 1/18 5/8 1/0 3/3 1/2 0/3 1/4
Parameswaran 24/15 4/2 0/3 3/1 4/1 6/0 5/4 NR
Saha 3/6 NR NR NR 2/3 NR NR 0/2
Zingg 19/20 17/33 NR NR 11/11 NR 2/2 2/6
Pham 34/27 13/9 18/16 3/1 4/5 6/0 3/10 3/2
Perry 13/17 2/3 5/8 5/4 4/6 1/2 2/5 NR
Hamouda NR 15/5 5/3 3/1 4/2 NR 3/0 NR
Safranek NR 19/13 NR 17/4 11/1 10/1 5/5 3/1
Schoppmann NR 5/17 NR 0/1 1/8 4/13 3/4 NR
Schröder NR NR NR NR 18/17 NR NR 7/11
Mehran NR 14/15 9/9 18/8 11/6 NR NR NR
Berger 31/32 10/22 1/6 NR 9/6 NR NR 5/4
Lee NR 11/20 NR NR 10/18 NR NR 4/8
Nafteux 44/61 17/47 11/13 13/6 5/10 NR 6/9 2/2
Yamasaki 26/38 7/15 3/6 0/2 6/4 17/20 3/5 0/2
Biere NR 14/35 1/1 1/0 7/4 1/8 1/1 3/1
Maas 21/33 9/13 3/6 NR 4/3 3/5 2/5 0/1
Briez 50/83 22/60 NR 6/4 8/6 NR NR 2/10
Kinjo 54/54 22/31 10/5 8/9 11/13 21/10 4/10 NR
Mamidanna NR 276/1419 165/1035 NR NR NR NR 46/274
Sihag NR 1/33 5/19 NR 0/2 NR 3/5 0/2
Sundaram 28/41 5/19 9/19 26/10 4/4 1/1 10/11 2/1
Tsujimoto 13/16 2/10 NR 1/1 7/3 2/2 1/4 1/5
Javidfar NR 9/26 29/56 19/33 5/7 3/0 22/38 3/7
Bailey NR 15/18 4/9 1/0 1/0 NR 6/15 2/2
Ichikawa 94/117 20/33 17/38 4/5 14/27 60/77 2/2 0/8
Kitagawa NR 6/14 NR NR NR NR 13/20 2/1
Noble NR 14/18 10/7 NR 5/2 NR 2/2 1/1
Parameswaran 42/12 7/2 2/1 14/2 NR 2/1 6/3 3/1
Takeno 39/69 NR NR NR NR NR NR 4/15
Kubo 57/35 13/16 NR 2/0 10/7 37/14 18/19 2/2
Schneider 7/13 NR NR NR NR NR NR 0/2
Daiko 10/12 NR NR NR 6/4 3/6 2/6 NR
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Statistical analysis
Data was analyzed using STATA 11 (Stata Corp LP, College
Station, Texas, 2011). Fixed or random effects models [31]
were used. Odds ratio (OR) was used for categorical vari-
ables, while weighted mean difference (WMD) was used for
continuous variables, such as operative time, harvested
lymph nodes, and blood loss [32]. Q test was used to check
the heterogeneity among each study. If the heterogeneity
was high (I2 > 50%), Random Effects Model was used to cal-
culate the pooled OR/WMD. Otherwise, the fixed effects
model was used [33]. If the heterogeneity test was statisti-
cally significant, sensitivity analysis, subgroup analysis,
Table 2 Outcomes of complication in included studies (Continued)
Kauppi 37/48 13/15 17/27 5/14 5/5 0/4 12/11 NR
Law NR 4/15 3/16 NR 0/2 4/8 NR NR
Chen NR 7/10 NR 2/0 1/0 NR 2/1 NR
Gao 31/36 13/11 NR 7/12 7/6 2/4 1/2 2/3
Shen 32/28 5/6 9/8 1/1 16/14 7/2 2/3 0/1
Liu 22/38 5/21 4/13 3/5 2/4 3/4 3/5 1/3
Mao 14/16 0/2 1/6 0/1 8/1 5/3 NR NR
Wang 90/145 12/23 21/36 11/13 26/32 6/7 8/16 2/11
MU 28/22 6/4 NR NR 12/4 NR NR 1/1
Meng 24/41 9/24 4/11 2/2 6/7 4/4 3/4 1/4
Zhang NR 4/7 3/5 3/2 3/2 2/1 2/7 NR
Chen 14/19 2/4 3/5 NR 2/3 4/5 1/1 NR
Yang 19/31 NR NR NR NR NR NR NR
Li 32/137 8/51 9/34 2/5 19/45 18/49 4/19 3/16
AL anastomotic leak, RLNP recurrent laryngeal nerve palsy, STR surgical technology-related, Mortality in-hospital/30-day mortality
Table 3 Differences between MIO and OE surgery patients
Variables No. studies WMD/OR (95%CI) PV PQ I
2 (%) PE
Age, years 57 (n = 15790) −0.343 (−1.200, 0.514) 0.433 <0.05 68.1 0.059
NT 34 (n = 5138) 1.364 (1.042,1.785) 0.024 <0.05 73.0 0.362
Comorbidity
Cardiovascular 16 (n = 10337) 0.913 (0.815,1.022) 0.112 0.030 44.2 0.930
Pulmonary 15 (n = 9779) 0.949 (0.819,1.099) 0.485 0.881 0 0.722
Diabetes 15 (n = 9983) 0.942 (0.798,1.111) 0.476 0.457 0 0.082
Operating time, min 46 (n = 6260) 24.427 (10.912,37.943) <0.05 <0.05 96.1 0.155
Blood loss, ml 40 (n = 5285) −196.060 (−255.195,-136.926) <0.05 <0.05 98.9 0.592
LN harvest 46 (n = 6390) −1.275 (−5.851,3.301) 0.585 <0.05 99.8 0.786
LOS, day 45 (n = 13899) −3.660 (−4.891,-2.428) <0.05 <0.05 86.0 0.175
ICU stay, day 27 (n = 10761) −1.599 (−2.680, −0.518) 0.004 <0.05 98.2 0.078
Complication
Total complication 35 (n = 5991) 0.700 (0.626,0.781) <0.05 0.012 38.5 0.178
Pulmonary 50 (n = 14781) 0.527 (0.431, 0.645) <0.05 <0.05 60.3 <0.05
Circulatory system 36 (n = 12883) 0.770 (0.681,0.872) <0.05 0.427 2.4 0.386
Digestive system 21 (n = 4081) 1.097 (0.835,1.442) 0.507 0.083 31.7 0.664
AL 50 (n = 7528) 1.023 (0.870,1.202) 0.785 0.304 8.5 0.018
RLNP 37 (n = 5429) 1.108 (0.917,1.339) 0.289 0.089 24.8 0.014
STR 39 (n = 5991) 0.639 (0.522,0.781) <0.05 0.918 0 0.206
Mortality 38 (n = 14132) 0.668 (0.539,0.827) <0.05 0.944 0 0.508
NT neoadjuvant therapy, LN lymph node, LOS length of hospital stay, ICU intensive care unit, AL anastomotic leak, RLNP recurrent laryngeal nerve palsy, STR
surgical technology-related, Mortality in-hospital/30-day mortality, PV the P value for pooled, PQ the P value for Q test, PE the P value for Egger’s test
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and Galbraith Plot Analysis were performed to find out
potential origin of heterogeneity. Egger’s Test and Begg’s
Funnel Plot were used for diagnosis of potential publica-
tion bias [34]. A P value <0.05 was considered as statistical
significance. Duval and Tweedie nonparametric “trim and
fill” procedure was used to assess the possible effect of
publication bias [35].
The Newcastle Ottawa Quality Assessment Scale was used
to assess the validity and quality of studies [36], as recom-
mended in the Cochrane Handbook [37]. This scale assigns
a star rating based on pre-specified criteria. A total number
of quality star ranged from one (low quality) to nine (high
quality). A maximum of one star can be attained for each
category, except comparability, which has maximum of two
stars. The more the stars, the higher is the quality of study.
Results
Study characteristics
A flow chart of the literature search process is shown in
Fig. 1. A total of 1021 unique records were identified by
search strategy; 917 records were excluded; 16 studies
were meta-analyses or systematic overviews [14–19]; ten
were review; and four were letter; nine studies did not
compare the outcomes of interest [3, 5–12], and six stud-
ies were duplicate to previous study. Therefore, 57 studies
containing 15,790 cases (both MIO and OE) were in-
cluded in this meta-analysis [30, 38–93].
Preoperative clinical data as well as quality star ran-
ging from 6 to 8 are shown in Table 1. Of 15,790
cases, 5235 (33.2%) were MIO and 10,555 (66.8%)
were OE. Thirty one studies were done in European
countries and 26 in Asian countries, where 13 were
from China [45–57]. Moreover, 39 studies involved
total MIE, 12 studies thoracoscopic-assisted MIE
(TA), and seven studies were hybrid (TA +MIE).
TNM staging were reported in 40 studies (6265
cases), where 1973 patients (64.4%) in the MIO group
and 1042 patients (32.5%) in the OE group were of
early stage (stages I and II), mainly male (78.4%
(MIO) vs 68.3% (OE)).
Preoperative clinical data
Fifty-seven studies reported patient’s age. There was no
statistical significance between two groups after pooled


















































































































Fig. 2 Meta-analysis for MIE and total complications
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analysis (WMD = −0.343, 95%CI = −1.200 ~ 0.514, PV <
0.433). Thirty-three studies (5243 cases) reported that
the patients in MIE group received more neoadjuvant
therapy (Table 3, pooled OR = 1.364, 95% CI = 1.042 ~
1.785, PV = 0.024). Sixteen studies reported preoperative
comorbidity, where there was no statistical significance
between two groups (PV > 0.05).
Postoperative data
Forty-six studies (6260 cases) reported that operative
time was higher in MIO group (Table 3, pooled WMD=
1.364, 95% CI = 10.912 ~ 37.943, PV < 0.05). Forty studies
(5285 cases) reported less blood loss in MIO group
(WMD = −196, 95% CI = −255.195 ~ −136.926, PV <
0.05). Duration of hospital stay (13,899 cases), including
ICU stay (10,761 cases), were found to be significantly
lower in MIO group (WMD = −1.599, 95% CI = (−2.680
~ −0.518,PV < 0.05 and WMD= −3.66, 95% CI = −4.891
~ −2.428, PV < 0.05). There was no significant difference
between two groups in forty-six studies (6390 cases) re-
ported for harvested lymph nodes (Table 3, WMD =
−1.275, 95% CI = −5.851 ~ 3.301, PV = 0.585). There was
significant heterogeneity in the outcome among all the
indices of postoperative data. Stratified analysis was per-
formed according to ethnicity (Asian/Caucasian);
however, heterogeneity still existed in subgroups. We
then gradually removed small sample size, with emphasis
on not altering the overall qualitative results.
Complications
MIO and total complications
Thirty-five studies including 5991 cases reported total
complications, where 41.5% (1206/2907) were allocated
to MIE group and 48.2% (1486/3084) were allocated to
OE group, with overall morbidity of 44.9% (2692/5991)
(see Table 2).
Low heterogeneity was found among studies (I2 =
38.5%, PQ = 0.012), so the fixed effects model was used
(see Table 3). The pooled OR = 0.70, 95% CI = 0.626 ~
0.781, PV < 0.05 indicated total complication was signifi-
cantly lower in MIO group (Fig. 2). Publication bias was
assessed by Egger’s Test and Begg’s Funnel Plot; no pub-
lication bias could be discovered (PE = 0.178).
MIO and pulmonary complications
Fifty studies including 14,781 cases reported pulmonary
complications, where 17.1% (813/4761) were in MIO
group and 22.6% (2264/10,020) were in OE group, with
overall morbidity of 20.8% (3077/14,781).
Fig. 3 Meta-analysis for MIE and pulmonary complications
Yibulayin et al. World Journal of Surgical Oncology  (2016) 14:304 Page 8 of 17
There was very strong evidence of reduced risk of
pulmonary complications in the MIO group (OR =
0.527, 95%CI = 0.431 ~ 0.645, PV < 0.05), with statistical
heterogeneity (I2 of 60.3%, PQ = 0.012) (Fig. 3, Table 3).
In order to find out other sources of heterogeneity,
Galbraith Plot Analysis was performed to identify
which study results in the heterogeneity (Fig. 4).
Pham et al. [52] and Mamidanna et al. [66] were out-
liers from the Galbraith Plot Analysis and I2 values












Fig. 4 Galbraith plot of MIE and pulmonary complications









Fig. 5 Begg’s Test of MIE and pulmonary complications
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CI = 0.425 ~ 0.592, PV < 0.05, I
2 = 26.6%, PQ = 0.05).
However, the funnel plot figure (Fig. 5) showed sig-
nificant statistical difference (PE < 0.05), indicating the
possibility of publication bias.
MIO and mortality
Thirty-eight studies addressed the mortality (MIO 4379
vs OE 9753). The mortality risk was 3.8% (124/4379) in
MIO group versus 4.5% (437/9753) in OE group. There
was very strong evidence of reduced mortality in MIO
group (OR = 0.668, 95% CI = 0.539 ~ 0.827, PV < 0.05),
with statistical homogeneity (I2 of 0%, PQ = 0.944)
(Fig. 6).
MIO and cardiovascular complications
Thirty-six studies reported cardiovascular complications
(MIO 3745 vs OE 9138). There was very strong evidence
of reduced cardiovascular complications in MIO group
(OR = 0.770, 95% CI = 0.681 ~ 0.872, PV < 0.05), with
statistical homogeneity (I2 of 2.4%, PQ = 0.427) (Fig. 7).
MIO and surgical technology related (STR) complications
Thirty-nine studies reported STR complications
(MIO2933 vs OE 3058). There was very strong evidence
of reduced STR complications in MIO group (OR =
0.770, 95% CI = 0.681 ~ 0.872, PV < 0.05), with statistical
homogeneity (I2 of 2.4%, PQ = 0.918) (Fig. 8 and Table 3).
MIO and gastrointestinal complications
Twenty-one studies reported gastrointestinal complica-
tions (MIO 1872 vs OE 2209). There was no evidence of
reduced gastrointestinal complications in MIO group
(OR = 1.097, 95% CI = 0.835 ~ 1.442, PV = 0.507), with
statistical homogeneity (I2 of 31.7%, PQ = 0.083)
(Table 3).
MIO and anastomotic leak (AL)
Fifty studies reported anastomotic leak (MIO 3680 vs
OE 3848). There was no evidence of reduced anasto-
motic leak in MIO group (OR = 1.023, 95% CI = 0.870 ~
1.202, PV = 0.785), with statistical homogeneity (I
2 of
8.5%, PQ = 0.304) (Table 3).
Fig. 6 Meta-analysis for MIE and Mortality
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MIO and recurrent laryngeal nerve palsy (RLNP)
Thirty-seven studies reported recurrent laryngeal nerve
palsy (MIO 2624 vs OE 2805). There was no evidence of
reduced RLNP in MIO group (OR = 1.108, 95% CI =
0.917 ~ 1.339, PV = 0.289), with statistical homogeneity
(I2 of 24.8%, PQ = 0.089) (Table 3).
Publication bias analysis
Publication bias was assessed by Egger’s Test and Begg’s
Funnel Plot. Begg’s Funnel Plot is shown in Fig. 5, with
significant statistical difference (PE < 0.05) (Table 3). This
indicated the possibility of publication bias, so sensitivity
analysis using “trim and fill” method was carried out,
with the aim to impute hypothetically negative unpub-
lished studies, to mirror the positive studies that cause
funnel plot asymmetry [35], and to show consistent and
stable results between MIO and pulmonary complica-
tions (Fig. 9), anastomotic leak, and recurrent laryngeal
nerve palsy.
Sensitivity analysis
As sample size for cases and controls in all studies is not
same (ranging from 9 to 6347), we gradually removed small
sample size without altering the qualitative overall results.
According to the sensitivity analysis shown in Fig. 10, we re-
moved the Mamidanna et al. [66], without alteration, where
I2 values decreased, indicating that the results were stable.
Discussion
MIO has been investigated for decades and is considered
to be advantageous compared to OE. However, in the
previous studies, the analyzed groups of patients who
underwent MIO were small and the reports were mostly
retrospective comparative studies, and there was no con-
sensus as to which operative method is superior [94].
Therefore, an updated meta-analysis is performed, which
includes the largest and the most complete collections
of published data.
We found higher operative duration in the MIO
group, consistent with Kunisaki’s [40], Shiraishi’s [45],





















































































































Fig. 7 Meta-analysis of MIE and cardiovascular complications
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and randomized controlled trials [30] reported, perhaps
due to surgeons’ familiarization with a new and complex
techniques. Blood loss in the MIO group was found to
be lower compared with OE, in accordance with the re-
sults of several case reported and recently published
meta-analyses [14, 20].
A shorter hospital stay in the MIO group indicated a
faster postoperative recovery than OE group, consistent
with other published meta-analyses [14, 20, 21, 30].
We did not find a significant number of harvested
lymph nodes in the MIO group [23]. However, signifi-
cant heterogeneity was seen among all indices of postop-
erative data, explained by the fact that postoperative
data are dependent on operator and tumor
characteristics.
Total complication rates varied between 20.5 and
63.5% (Table 2). The MIO group showed lower total
complication rates, pulmonary complications occupying
the major part. However, a number of studies have re-
ported significantly lower pulmonary complications for
those who underwent MIO 17.1% (813/4761) versus OE
22.6% (2264/10,020), with overall morbidity of 20.8%
(3077/14,781), consistent with the result of 3.1–37.0%
from other studies [15–20, 45, 58–76, 95].
Kinugasa et al. and Ferguson et al. [95, 96] noted that
development of pneumonia post procedure was associ-
ated with worse prognosis for overall survival (P < 0.01).
In addition, Dumont et al. [97] also showed that two
thirds of all fatal complications were respiratory in na-
ture. Sauvanet et al. [98] reported that pulmonary mor-
bidity was associated with age >60, with no significant
differences in two groups.
The pooled OR of 0.527 showed MIO to be more ad-
vantageous than OE in reducing pulmonary morbidity.
Although statistical heterogeneity and publication bias
were found, we demonstrated the superiority of MIO
through statistical methods. However, several factors
have been associated with pulmonary complications post
procedure, including preoperative status, intraoperative
details, and postoperative details [99].
Gex et al. reported that overall 30-day mortality rate
was 4.3% between 2004 and 2009, compared with 7.6% in
Fig. 8 Meta-analysis of MIE and STR complications
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2002 and 2003, and 11.7% in 1997 and 1999 [100]. Our
study found the overall 30-day mortality rate of 5.8% and
the pooled OR of 0.668, showing that MIO to be advanta-
geous than OE in reducing mortality. The main advan-
tages of MIO over conventional OE are minimal trauma,
small incision, less blood loss, etc. [6]. Other factors inde-
pendently associated with 30-day mortality included TNM
staging, preoperative neoadjuvant therapy, comorbidity,
diabetes, increased age, and intraoperative blood loss.
However, there was no difference between two groups in
terms of age and comorbidity. We found increased num-
ber of patients having neoadjuvant therapy in MIO group
and patients selected for MIO were always in the early
stages. The bias in the selection of patients may have in-
fluenced the accuracy of the conclusion, which should be
taken into consideration.
Arrhythmia, heart failure, pulmonary embolism, and
other cardiovascular complications are recognized as
common problems that caused significant morbidity and
mortality. Zhou et al. [24] reported significant decrease
in the morbidity of arrhythmia and pulmonary embolism
in MIO group. Corresponding to this, (see Table 3), we
found MIO to be superior to OE in reducing morbidity
of system complications, according to the pooled OR =
0.777. Weidenhagent et al. [101] also indicated that the
perforation from minimally invasive surgery as such
could decrease the risks leading to arrhythmia.
Rizk et al. [102] indicated that “surgical technology re-
lated complications,” defined as complications caused
directly by operative techniques, had no relationship
with overall survival post procedure. However, in our
meta-analysis, we found strong evidence of reduced risk
of STR complications in the MIO group.
Anastomotic leakage (AL) is a serious complication of
esophageal resection and is associated with significant
morbidity and mortality [4]. In accordance with Zhou et
al’s conclusion [17], we also did not find the evidence of
reduced risk of anastomotic leak in the MIO group.
Similarly, we also did not find any significant differences
in two groups in terms of RLNP and gastrointestinal
complications.
Although we conducted comprehensive meta-analysis,
our study still has its limitations. (1) Out of 57 studies,
only one study is randomized controlled trial (RCT),
while others were case-control or cross-sectional de-
signs. Seven studies were of small sample size, which
might have influenced the final results of our study. (2)
Patients selected for MIO are unlikely to have been rep-
resentative of the general population of esophageal can-
cer. We found more patients having neoadjuvant
therapy in MIO group, and the patients selected for
MIO were always in the early stages, creating selection
bias. (3) In order to highlight the advantages of MIO,
surgeons would prefer to publish positive results, and
Fig. 9 The “trim and fill” method for MIE and pulmonary complications
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unsatisfactory results may have been less inclined in
their papers; all these can lead to publication bias. (4) In
our study, we compared MIO with OE. MIO consists of
different procedures. Although we performed a sub-
group analysis according to different procedures, the re-
sults were also not qualitatively altered. However, lots of
differences exist among these procedures, which will
affect the quality of this meta-analysis, and the learning
curve of MIO is quite steep, which may influence the
outcome of MIE. These limitations may result in an
overestimation or underestimation of the effect of MIO.
In addition, 19 studies did the follow-up visit, and all
those studies indicated that the 3-year survival, 5-year
survival, and overall recurrence rate did not differ be-
tween the two groups. Due to the difficulty in data ex-
traction, no pooled analysis was performed, which may
have influential role in this study.
Conclusions
In summary, this meta-analysis indicates that MIO is a
feasible and a reliable surgical procedure and is superior
to OE, with less perioperative complications and in-
hospital mortality. However, due to certain limitations of
this study, as aforementioned above, further large sample
and RCT studies are needed to estimate the effect of
MIO and establish the guidelines for future.
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